Research To Practice | Oncology Videos

Featuring an interview with Dr Amy DeZern, including the following topics: Case: A man in his mid 60s with myelodysplastic syndromes (MDS) and comorbid psoriatic arthritis and osteoarthritis (0:00) Association between autoimmune conditions and MDS; impact of coexisting autoimmune disease on MDS treatment selection (7:55) Case: A man in his late 50s presenting with a chronic cough and cytopenia (15:10) Case: A woman in her early 70s with significant weight loss, fatigue and night sweats (21:06) MDS risk evaluation and stratification; optimal management of secondary MDS; treatment options for MDS progressing to acute myeloid leukemia (28:31) Myths and misperceptions about MDS among general medical oncologists; novel agents under evaluation for MDS (34:17) Considerations for off-label use of venetoclax for high-risk MDS; clinical pearls about managing low-risk MDS (39:00) CME information and select publications

Featuring a slide presentation and related discussion from Dr Amy DeZern, including the following topics: Classification of myelodysplastic syndromes (MDS) (0:00) Available data with and optimal selection of commericially available therapies for MDS (6:54) Emerging data with novel MDS therapies from clinical trials (21:34) CME information and select publications

Featuring perspectives from Dr Elizabeth O'Donnell, including the following topics: Introduction: Quality of Life in Multiple Myeloma (0:00) CAR (Chimeric Antigen Receptor) T-Cell Therapy (9:29) Bispecific Antibodies (33:08) Belantamab Mafodotin (43:11) CME information and select publications

Featuring a slide presentation and related discussion from Dr Rachna Shroff, including the following topics: Colorectal Cancer (0:00) Gastroesophageal Cancers (19:20) Hepatocellular Carcinoma (27:20) Biliary Tract Cancers (37:59) Pancreatic Cancer (41:33) CME information and select publications

Featuring an interview with Dr Rachna Shroff, including the following topics: Novel targets and emerging strategies for the treatment of pancreatic cancer (0:00) Current and emerging approaches to the care of patients with biliary tract cancers (6:28) Efficacy and tolerability of approved and investigational therapies for hepatocellular carcinoma ()18:42) Incorporating immuno-oncology agents and targeted strategies into the care of patients with gastroesophageal cancer (28:07) Evaluating current and emerging targeted approaches to the treatment of colorectal cancer (35:28) CME information and select publications

Featuring perspectives from Dr Matthew Smith, including the following topics: Introduction: Abemaciclib for Prostate Cancer? (0:00) Case: A man in his early 70s with a PSA of 150 ng/mL, Gleason 4 + 4 and upper abdominal adenopathy — Jennifer L Dallas, MD (9:30) Case: A man in his late 60s with Gleason 4 + 4, PSA of 147 ng/mL and a negative CT — David S Morris, MD (34:30) Case: A man in his late 60s with coronary artery disease and Gleason 4 + 4 who underwent external beam radiation therapy (EBRT) in 2013 and now has increasing PSA of 3.8 with a 6-month doubling time — Gurveen Kaur, MD (37:56) Case: A man in his mid 60s who experiences M0 progression after EBRT followed by androgen deprivation therapy (ADT) but refuses to continue ADT — Henna Malik, MD (41:44) Case: A man in his early 50s with a slowly rising PSA (now 1.31) after radical prostatectomy and salvage radiation therapy; PSMA PET scan denied by insurance, now appealed — Kapisthalam (KS) Kumar, MD (50:23) Case: A man in his late 70s with Gleason 5 + 4 and a PSA of 23 ng/mL increasing after EBRT followed by ADT, cryoablation and enzalutamide; after a response, 18F-fluciclovine PET shows subtle focus of uptake in left prostate — Susmitha Apuri, MD (57:06) CME information and select publications

Featuring perspectives from Drs Danielle Brander, Matthew Davids, Anthony Mato and William Wierda, including the following topics: Front-Line Chronic Lymphocytic Leukemia (CLL; Standard-Risk Patients) — Anthony R Mato, MD, MSCE (0:00) CLL in 2022: Front-Line Therapy for Patients with High-Risk Disease — Danielle Brander, MD (28:50) Fixed-Duration Targeted Therapy for CLL — William G Wierda, MD, PhD (59:26) Novel Investigational Agents and Strategies for CLL — Matthew S Davids, MD, MMSc (1:13:11) CME information and select publications

Featuring a slide presentation and related discussion from Dr Rebecca Heist, including the following topics: Targeting MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC) (0:00) Efficacy and tolerability of MET tyrosine kinase inhibitors in patients with NSCLC and MET alterations (12:35) Mechanisms of resistance to therapies for MET-altered NSCLC (19:11) Evaluating the role of antibody-based therapy in the treatment of MET-altered NSCLC (25:17) CME information and select publications

Featuring an interview with Dr Rebecca Heist, including the following topics: Mechanism of action and toxicity of amivantamab in patients with MET-driven non-small cell lung cancer (NSCLC) (0:00) Potential role of MET inhibitors as pantumor treatment for MET-altered cancer (2:27) Selection and sequencing of targeted therapy for patients with MET-altered NSCLC (5:24) Managing MET-altered NSCLC in patients with brain metastases (7:55) Immune checkpoint inhibitors and MET-targeted therapy for patients with NSCLC and MET alterations (9:27) Case: A woman in her mid 60s with no smoking history and newly diagnosed NSCLC with a MET exon 14 skipping mutation (14:55) Case: A woman in her mid 70s with MET-amplified relapsed NSCLC with an EGFR L858R mutation (24:02) Novel agents and strategies for the management of MET-altered NSCLC (32:00) CME information and select publications

Featuring a slide presentation and related discussion from Dr Brady Stein, including the following topics: Introduction to myelofibrosis (MF) and the use of JAK inhibitors as therapy for MF (0:00) Available efficacy and safety data with ruxolitinib for MF (4:17) Pivotal data leading to the approval of fedratinib (13:11) Unique features of pacritinib and current role in treatment algorithm for MF; other novel therapies under investigation (19:17) CME information and select publications